Phreesia sells patient intake and engagement software to physician practices and pharmacies, including digital check-in kiosks, electronic consent and payment tools, and its Pharma-facing data and services. The moat is embedded workflow: once a clinic runs its front desk through Phreesia, switching is disruptive, which helps explain the 67.5% gross margin. Revenue is growing 10.4%, and the stock trades at 12.0 times forward earnings against a trailing 64.9 times, so the story turns on whether GAAP profitability catches up with the 5.9% operating margin. A forward multiple that low on a company with a 10% top line and a 685 million dollar market cap, outside any index, is the kind of gap worth checking against consensus and the margin trajectory before going further.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 20 Oct 2026, 14:06 CEST | Rating | Undervalued | first publication | $11.28 |
| 20 Oct 2026, 14:06 CEST | Fair value | $15.61 | $15.40 | $11.28 |
| 15 Oct 2026, 00:00 CEST | ACCE price target | $12.50 | first publication | $10.75 |
| 15 Oct 2026, 00:00 CEST | Fair value | $15.40 | $14.93 | $10.75 |
| 11 Oct 2026, 00:00 CEST | Fair value | $14.93 | $5.90 | $10.81 |
| 6 Oct 2026, 00:00 CEST | Fair value | $5.90 | $5.79 | $10.07 |
| 4 Oct 2026, 00:00 CEST | Fair value | $5.79 | $5.95 | $10.07 |
| 29 Sept 2026, 00:00 CEST | Fair value | $5.95 | $6.11 | $10.15 |
| 16 Sept 2026, 00:00 CEST | Fair value | $6.11 | $6.23 | $10.42 |
| 8 Sept 2026, 00:00 CEST | Fair value | $6.23 | $5.99 | $10.94 |
Answered from Phreesia Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| PHR Phreesia Inc. Common Stock | $12.70 | $16 | 19% below | 74.7x | 3.1% | 55 | 67 |
| TALK Talkspace Inc. Common Stock | $5.25 | - | - | - | 0.2% | 27 | 52 |
| SOPH SOPHiA GENETICS SA Ordinary Shares | $7.35 | - | - | - | -101.2% | 38 | 50 |
| WEAV Weave Communications Inc. Common Stock | $7.40 | $4 | 77% above | - | -25.1% | 43 | 53 |
| HSTM HealthStream Inc. Common Stock | $35.16 | $21 | 71% above | 46.7x | 6.0% | 71 | 71 |
| RAY-B.ST RaySearch Laboratories AB (publ) | kr 191.90 | kr 164 | 17% above | 30.9x | 26.0% | 85 | 41 |
| EVH Evolent Health Inc Class A Common Stock | $4.80 | - | - | - | -67.0% | 21 | 48 |
Where PHR ranks against its sector peers on each metric.